Skip to main content

The RheumNow Week in Review – 17 February 2017

Feb 17, 2017 3:30 am

Dr. Jack Cush reviews this week's news and information from the 2017 RWCS meeting in Maui.

  1. 5yr study of inpatient gout flares - predictors include GI Bleed, urinary catheter or Abx use. Dr Orrin Troum lectures from RWCS2017 by
  2. RA patients having all 3 of the following factors (seropositivity; high IgG levels; detectable serum IL-33) in a cohort study shown to have a 100% response to Rituximab
  3. Abbvies JAK inhibitor (ABT-494) has a name, Uptacitinib, is currently in phIII trials. #RWCS 2017 info from Dr. M Genovese
  4. Rare cause of RA with lymphadenopathy - Think Angioimmunoblastic T-cell lymphoma: rare; with LN, fever, rash, organomegaly polyarthritis
  5. 43% of 550 RA pts have ILD. 70% occurred within 10 yrs of RA onset, w/ reticular & ground-glass patterns, most NSIP
  6. Study shows HBV reactivation w/ tocilizumab Rx only with Chronic HBV, not Resolved HBV - Do HBV testing with TCZ!
  7. Kikuchis disease commonly associates with SLE - review of 138 patients with fever, necrotizing lymphadenitis, less nephritis
  8. In animal models, abatacept and tofacitinib shown effective in treating suppressing Chikungunya arthritis.
  9. Brodalumab is FDA Approved for Psoriasis but with a Black box warning for suicide
  10. Baricitinib Approved in the EU for Use in Rheumatoid Arthritis  
  11. BEAM Study: Baricitinib Beats Placebo and Adalimumab in Rheumatoid Arthritis
  12. Crohn's Arthritis Linked to E. Coli Infection.
  13. Immunosuppressives Fail to Benefit Early Skin Scleroderma
  14. Top Ten Things Rheumatologists Should Know When Ordering Imaging
  15. The Negotiator 
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.